JP2014504866A5 - - Google Patents

Download PDF

Info

Publication number
JP2014504866A5
JP2014504866A5 JP2013547846A JP2013547846A JP2014504866A5 JP 2014504866 A5 JP2014504866 A5 JP 2014504866A5 JP 2013547846 A JP2013547846 A JP 2013547846A JP 2013547846 A JP2013547846 A JP 2013547846A JP 2014504866 A5 JP2014504866 A5 JP 2014504866A5
Authority
JP
Japan
Prior art keywords
single variable
variable domain
immunoglobulin single
polypeptide
tgfbetarii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013547846A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014504866A (ja
JP6062375B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/050061 external-priority patent/WO2012093125A1/en
Publication of JP2014504866A publication Critical patent/JP2014504866A/ja
Publication of JP2014504866A5 publication Critical patent/JP2014504866A5/ja
Application granted granted Critical
Publication of JP6062375B2 publication Critical patent/JP6062375B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013547846A 2011-01-06 2012-01-04 Tgf−ベータ受容体iiに結合するリガンド Expired - Fee Related JP6062375B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161430235P 2011-01-06 2011-01-06
US61/430,235 2011-01-06
PCT/EP2012/050061 WO2012093125A1 (en) 2011-01-06 2012-01-04 Ligands that bind tgf-beta receptor ii

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016205978A Division JP6453289B2 (ja) 2011-01-06 2016-10-20 Tgf−ベータ受容体iiに結合するリガンド

Publications (3)

Publication Number Publication Date
JP2014504866A JP2014504866A (ja) 2014-02-27
JP2014504866A5 true JP2014504866A5 (cg-RX-API-DMAC7.html) 2015-01-08
JP6062375B2 JP6062375B2 (ja) 2017-01-18

Family

ID=45444622

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013547846A Expired - Fee Related JP6062375B2 (ja) 2011-01-06 2012-01-04 Tgf−ベータ受容体iiに結合するリガンド
JP2016205978A Expired - Fee Related JP6453289B2 (ja) 2011-01-06 2016-10-20 Tgf−ベータ受容体iiに結合するリガンド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016205978A Expired - Fee Related JP6453289B2 (ja) 2011-01-06 2016-10-20 Tgf−ベータ受容体iiに結合するリガンド

Country Status (22)

Country Link
US (3) US9150651B2 (cg-RX-API-DMAC7.html)
EP (1) EP2661449B1 (cg-RX-API-DMAC7.html)
JP (2) JP6062375B2 (cg-RX-API-DMAC7.html)
KR (1) KR101886898B1 (cg-RX-API-DMAC7.html)
CN (1) CN103443126B (cg-RX-API-DMAC7.html)
AU (1) AU2016203609A1 (cg-RX-API-DMAC7.html)
BR (1) BR112013016917A2 (cg-RX-API-DMAC7.html)
CA (1) CA2823104A1 (cg-RX-API-DMAC7.html)
CL (1) CL2013001975A1 (cg-RX-API-DMAC7.html)
CO (1) CO6811807A2 (cg-RX-API-DMAC7.html)
CR (1) CR20130376A (cg-RX-API-DMAC7.html)
DO (1) DOP2013000162A (cg-RX-API-DMAC7.html)
EA (1) EA201391012A1 (cg-RX-API-DMAC7.html)
ES (1) ES2627299T3 (cg-RX-API-DMAC7.html)
IL (1) IL227254A0 (cg-RX-API-DMAC7.html)
MA (1) MA34820B1 (cg-RX-API-DMAC7.html)
MX (1) MX2013007936A (cg-RX-API-DMAC7.html)
PE (1) PE20140982A1 (cg-RX-API-DMAC7.html)
PH (1) PH12013501397A1 (cg-RX-API-DMAC7.html)
SG (1) SG191762A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012093125A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201304726B (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
CN103443126B (zh) * 2011-01-06 2016-11-23 葛兰素集团有限公司 结合TGFβ受体II的配体
SG194982A1 (en) * 2011-06-23 2013-12-30 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
KR102233349B1 (ko) * 2013-03-15 2021-03-31 에이씨 이뮨 에스.에이. 항-타우(tau) 항체 및 사용 방법
CN105164157B (zh) 2013-04-29 2024-05-28 豪夫迈·罗氏有限公司 Fc-受体结合的修饰的非对称抗体及使用方法
HK1225742A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma, Inc. TGF-β受体II型变体及其用途
CA2931309C (en) * 2013-11-21 2022-06-21 The Brigham And Women's Hospital, Inc. Compositions and methods for treating pulmonary hypertension
CN110981957B (zh) 2014-01-15 2024-12-24 豪夫迈·罗氏有限公司 具有改善的蛋白A结合作用的Fc区变体
EP3094649A1 (en) * 2014-01-15 2016-11-23 F. Hoffmann-La Roche AG Fc-region variants with modified fcrn-binding properties
EP3174550B1 (en) * 2014-08-01 2020-01-29 The Brigham and Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
MY193078A (en) 2015-06-24 2022-09-26 Hoffmann La Roche Anti-transferrin receptor antibodies with tailored affinity
CN108348578B (zh) 2015-08-04 2022-08-09 阿塞勒隆制药公司 用于治疗骨髓增生性病症的方法
WO2017041114A2 (en) * 2015-09-03 2017-03-09 The Children's Mercy Hospital Anti-nicotinamide phosphoribosyltransferase antibody genes and methods of use thereof
CN108137697A (zh) 2015-10-02 2018-06-08 豪夫迈·罗氏有限公司 双特异性抗人cd20/人转铁蛋白受体抗体及使用方法
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
PL3374392T3 (pl) * 2015-11-13 2022-03-28 Ablynx Nv Ulepszone domeny zmienne immunoglobuliny wiążące albuminę surowicy
KR20180131557A (ko) * 2016-04-05 2018-12-10 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 면역요법에서의 tgf베타의 억제
RS64315B1 (sr) 2017-05-04 2023-08-31 Acceleron Pharma Inc Fuzioni proteini tgf-beta receptora tipa ii i njihove upotrebe
GB201807693D0 (en) * 2018-05-11 2018-06-27 Autolus Ltd Cell
WO2020009248A1 (ja) * 2018-07-04 2020-01-09 京都府公立大学法人 眼組織の線維化抑制用組成物
WO2021021528A1 (en) * 2019-07-26 2021-02-04 Board Of Trustees Of Michigan State University Methods of preventing or treating fatty degeneration of skeletal muscle
US20250270331A1 (en) * 2019-12-24 2025-08-28 Merus N.V. Tgf-beta-rii binding proteins
KR102314157B1 (ko) * 2020-01-10 2021-10-19 주식회사 뉴클릭스바이오 TGF-β 수용체에 특이적으로 결합하는 항체 및 이의 이용방법
US20220144956A1 (en) * 2020-11-06 2022-05-12 Xencor, Inc. HETERODIMERIC ANTIBODIES THAT BIND TGFbetaRII
IL305181A (en) 2021-02-15 2023-10-01 Takeda Pharmaceuticals Co Cell therapy compositions and methods for modulating tgf-b signaling

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026087A2 (en) 1993-05-14 1994-11-24 Connor Kim C O Recombinant protein production and insect cell culture and process
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
JP2001206899A (ja) * 1999-11-18 2001-07-31 Japan Tobacco Inc TGF−βII型受容体に対するヒトモノクローナル抗体及びその医薬用途
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
CA2447851C (en) 2001-06-28 2012-08-28 Domantis Limited Dual-specific ligand and its use
WO2003076567A2 (en) 2002-03-05 2003-09-18 Eli Lilly And Company Heterologous g-csf fusion proteins
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
DK1517921T3 (da) 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
EP3299393A1 (en) 2002-11-08 2018-03-28 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
AU2003290330A1 (en) 2002-12-27 2004-07-22 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
AU2004239065B2 (en) 2003-05-14 2008-05-15 Domantis Limited A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
AU2004220325B2 (en) 2003-06-30 2011-05-12 Domantis Limited Polypeptides
EP1675878A2 (en) 2003-10-24 2006-07-05 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
EP1729795B1 (en) 2004-02-09 2016-02-03 Human Genome Sciences, Inc. Albumin fusion proteins
EP1737962B1 (en) 2004-03-24 2010-09-01 Domantis Limited Gas1 universal leader
GB0418651D0 (en) 2004-08-20 2004-09-22 Medical Res Council Method
US20070012251A1 (en) 2005-07-07 2007-01-18 Martin Zucker Seal arrangement with corrosion barrier and method
CA2636854A1 (en) 2006-01-24 2007-08-02 Domantis Limited Ligands that bind il-4 and/or il-13
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
JO3096B1 (ar) * 2008-11-07 2017-03-15 Imclone Llc الأجسام المضادة لمستقبل ii مضاد tgfb
EA026097B1 (ru) * 2009-07-29 2017-03-31 Глаксо Груп Лимитед Однодоменные антитела против рецептора tgf-бета ii типа
US20120316071A1 (en) * 2009-11-04 2012-12-13 Vaughn Smider Methods for affinity maturation-based antibody optimization
CN103443126B (zh) * 2011-01-06 2016-11-23 葛兰素集团有限公司 结合TGFβ受体II的配体

Similar Documents

Publication Publication Date Title
JP2014504866A5 (cg-RX-API-DMAC7.html)
HRP20211053T1 (hr) Modificirani fgf-21 polipeptidi i njihove primjene
PH12013501397A1 (en) Ligands that bind tgf-beta receptor ii
JP2014158480A5 (cg-RX-API-DMAC7.html)
JP2017537612A5 (cg-RX-API-DMAC7.html)
JP2011514150A5 (cg-RX-API-DMAC7.html)
JP2018521691A5 (cg-RX-API-DMAC7.html)
WO2019079496A3 (en) Fully-human post-translationally modified antibody therapeutics
JP2017081939A5 (cg-RX-API-DMAC7.html)
MX2021012867A (es) Terapéutica de anticuerpos postraduccionalmente modificados completamente humanos.
HRP20161656T4 (hr) Sredstva za vezanje na cd33
JP2016536361A5 (cg-RX-API-DMAC7.html)
JP2017101068A5 (cg-RX-API-DMAC7.html)
JP2015529225A5 (cg-RX-API-DMAC7.html)
JP2016094424A5 (cg-RX-API-DMAC7.html)
JP2012511545A5 (cg-RX-API-DMAC7.html)
HRP20150799T1 (hr) Sastavi i postupci za protutijela protiv komplementnog proteina c5
JP2013520996A5 (cg-RX-API-DMAC7.html)
JP2016502515A5 (cg-RX-API-DMAC7.html)
NZ607394A (en) Vegf-binding molecules
HRP20210393T1 (hr) Anti-tfr antitijela i njihova uporaba u liječenju proliferativnih i upalnih poremećaja
JP2011519571A5 (cg-RX-API-DMAC7.html)
RU2015143886A (ru) Антитела к тау и способы применения
JP2014240408A5 (cg-RX-API-DMAC7.html)
JP2011506483A5 (cg-RX-API-DMAC7.html)